Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Ahead of Print

Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study

1 Service des Maladies Respiratoires, Hôpital d'Instruction des Armées Clermont Tonnerre, Brest, France
2 Centre Anti-Cancéreux François-Baclesse, Caen, France
3 Centre Hospitalier Intercommunal de Créteil, Créteil, France
4 Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France
5 CH de Quimper, Quimper, France
6 CH de Lorient, Lorient, France
7 CHU de Rouen, Rouen, France
8 CH de Draguignan, Draguignan, France
9 Institut de Cancérologie de Bretagne Occidentale, Brest, France
10 CH de La Roche-sur-Yon, La Roche-sur-Yon, France

Correspondence Address:
Christos Chouaïd,
Service de Pneumologie, Chi Creteil, 40 avenue de Verdun, 94010, Creteil
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_784_20

Purpose: Few data have been published on the management of patients with synchronous head-and-neck cancer (HNC) and lung cancer (LC). This observational study was undertaken to describe the management of these patients in multiple centers. Materials and Methods: All patients consecutively diagnosed with synchronous HNC and LC in 26 French centers were included. Information was collected on patients' clinical characteristics, management, and outcomes. Those characteristics and treatments were analyzed descriptively. Kaplan–Meier progression-free and overall survival probabilities were estimated. Results: The study included 132 patients: 83% male; median age: 63.7 (range: 62.1–65.4) years; all current or former smokers; Eastern Cooperative Oncology Group performance status: 0 or 1 for 21.9% or 65.9% of the patients, respectively; cardiovascular comorbidities: 63%; chronic obstructive pulmonary disease: 33%; and previous cancer: 11%. HNC histology was 98% squamous: 23.5% oral cavity, 26.5% oropharyngeal, 22.0% hypopharyngeal, and 28.0% laryngeal. LCs were mainly localized (47.7% Stage I and 9.9% Stage II): 38% squamous, 49% adenocarcinomas, and 13% others. LC diagnosis impacted HNC management for 38% of the patients, with a median time from HNC diagnosis to first HNC treatment of 40 days. HNC impacted LC management for 48% of the patients, with a median time from LC diagnosis-to-LC treatment interval of 41 days. Conclusions: Synchronous LC at HNC diagnosis impacted management and outcomes of both cancers. Specific recommendations should be elaborated to improve the management of these patients.

Print this article
  Search Pubmed for
    -  Paleiron N
    -  Gervais R
    -  Rousseau-Bussac G
    -  Game LB
    -  Chiappa AM
    -  Lamy R
    -  Guisier F
    -  Le Caer H
    -  Robinet G
    -  Bizieux A
    -  Chouaïd C
    -  GFPC
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded6    

Recommend this journal